Form 4: Enanta Pharmaceuticals Director Kristine Peterson Acquires Stock Options
SEC Form 4 Filing
Director Kristine Peterson acquired 15,700 stock options in Enanta Pharmaceuticals on March 6, 2024, exercisable over one year.
Summary
- On March 6, 2024, Kristine Peterson, a director of Enanta Pharmaceuticals, acquired 15,700 stock options.
- The exercise price of these options is $15.66.
- The options become exercisable monthly over one year, starting March 6, 2024, with the final installment vesting before the 2025 annual meeting of stockholders.
- The options expire on March 6, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of directors with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of transaction: Kristine Peterson acquired 15,700 stock options at an exercise price of $15.66. |
| 03/06/2024 | Options become exercisable monthly over one year, beginning from this date. |
| 03/06/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.